What is a soft tissue sarcoma?

Soft tissue sarcoma is a form of cancer that develops in the connective tissues—blood vessels, cartilage, fat, ligaments, lymph vessels, muscles, nerves, and tendons. These tumors most often occur in the arms and legs (60 percent of cases), but can also be found in the retroperitoneum, or back half of the belly (20 percent of cases), pelvis, spine, neck, head, chest, buttocks, or uterus.

Soft tissue sarcomas are rare, but occur more often than bone sarcomas. They are also more likely to metastasize (spread) before being diagnosed and to return after treatment. Some soft tissue sarcomas are more aggressive than others.

Types of soft tissue sarcoma

There are more than 50 subtypes of soft tissue sarcomas:

Among the tumors listed, UPS is the most common, followed by liposarcoma, leiomyosarcoma, and GIST.

Soft tissue sarcoma symptoms

Many soft tissue sarcomas don’t cause symptoms. Unlike other cancers, they may push body parts aside rather than grow into them. Still, the tumors may offer some signs such as a firm mass. These signs depend on where in the body the sarcoma develops.

Soft tissue sarcoma causes and risk factors

Doctors know that a particular soft tissue sarcoma called Kaposi sarcoma is caused by a virus called human herpesvirus 8 (HHV8). However, they don’t usually know what causes other soft tissue sarcomas, and you can’t typically reduce your risk of developing one.

Sometimes, radiation therapy can lead to the later development of soft tissue sarcoma, an uncommon side effect that occurs less frequently with newer types of radiation. Another radiation side effect, swelling called lymphedema, can also raise soft tissue sarcoma risk. Past workplace exposure to the chemicals chloride monomer, dioxin, or Agent Orange may also have ties to soft tissue sarcomas.

Some people inherit genetic variants (changes) tied to rare syndromes. These syndromes cause various symptoms and diseases and can raise the risk for some cancers, including sarcomas. The genetic syndromes tied to higher risk for soft tissue tumors include:

  • Carney-Stratakis syndrome: GIST
  • Familial GIST: GIST
  • Familial adenomatous polyposis (FAP): Desmoid tumor (benign)
  • Hereditary leiomyomatosis and renal cell cancer (HLRCC): Leiomyosarcoma in the uterus
  • Hereditary retinoblastoma: Fibrosarcoma, liposarcoma, leiomyosarcoma
  • Li–Fraumeni syndrome (LFS): Rhabdomyosarcoma and, much less frequently, fibrosarcoma, leiomyosarcoma, orbital (near the eyes) liposarcoma, and UPS
  • Neurofibromatosis type 1 (NF1): GIST, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, and UPS
  • Tuberous sclerosis complex: Various benign soft tissue tumors

A number of additional rare, genetic syndromes can also raise the risk for a type of rhabdomyosarcoma called embryonal rhabdomyosarcoma.

If one of these syndromes runs in your family, specialists at Penn Medicine can provide genetic testing and counseling.

Diagnosing soft tissue sarcoma

Taking scans is the first step in evaluating lumps or bumps that may be soft tissue sarcoma. Sometimes, that imaging clearly rules out sarcoma. If we need more information, we may recommend a biopsy to take a tissue sample from the lump or bump.

Soft tissue sarcoma diagnosis at Penn Medicine

Soft tissue sarcoma treatment at Penn Medicine

The primary goal of soft tissue sarcoma treatment is to remove the tumor. Surgeons specialized in various areas of the body work to remove soft tissue sarcomas in one piece with an appropriate border of normal tissue.

Orthopaedic oncologists lead treatment for the arms, legs, and pelvis, while surgical oncologists treat tumors in the retroperitoneum. Neurosurgeons work on spinal tumors and gynecologic oncologists on uterine tumors. Head and neck surgeons may participate in tumor removals involving the head and neck as well.

To reduce the chances of soft tissue sarcoma returning after surgery, we treat some tumors with radiation therapy first. This treatment is most common for tumors in the arms and legs.

For soft tissue sarcoma that spreads, we may recommend chemotherapy, targeted therapy, or immunotherapy. Our team also participates in clinical trials to find more effective solutions for advanced disease.

Treating soft tissue sarcoma

National Cancer Institute "Designated Comprehensive Cancer Center" badge on top of exterior shot of the Perelman Center for Advanced Medicine

Rated “exceptional” by The National Cancer Institute

Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Our status as a national leader in cancer care is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 7 such centers in the United States. The ACC is also a member of the National Comprehensive Cancer Network, one of a select few cancer centers in the U.S., that are working to promote equitable access to high-quality, advanced cancer care.

Related specialties

Patient stories

Tool measures tumor growth for less uncertainty between scans

Neuroradiologists have developed the first-ever tool that gives a real-time assessment of an individual’s tumor, and relieves anxiety between scans.

Patient puts national spotlight on cancer clinical trials

As Kate Korson recently shared on Good Morning America, both she and her mother participated in clinical trials at Abramson Cancer Center.

Finding triple-negative breast cancer at 33, she chose ‘Team Penn’

Shocked to learn she had stage III breast cancer, Kate Korson knew just where to go. She flew home to Penn Medicine, where a clinical trial saved her life.

How pickleball (and Penn Medicine) saved one patient’s life

With teamwork and determination, specialists at Penn Medicine solved Ronnie Recchia’s life-threatening medical mystery and got him back in the game.

Redefining the cancer bell to celebrate with meaning

The Abramson Cancer Center wants to make bell-ringing more inclusive, so cancer patients can recognize their moments to cheer, large and small.

Faith, fate, and families

At the Basser Center for BRCA at Penn, a unique philanthropic investment is making rapid progress toward preventing and treating heritable cancer.

In the face of skin cancer, proton made all the difference

A Lancaster man and father of two reveals how proton therapy helped him beat skin cancer and reclaim his life.

Epilepsy surgery gives patient a new lease on life

Minimally invasive laser interstitial thermal therapy (LITT) surgery reduced the epilepsy symptoms a patient had experienced for more than 30 years.

A grateful patient pays it forward to treat uterine cancers

Dalia Jakas credits her doctor with curing her uterine cancer without harming her quality of life. Now, she’s paying it forward for future patients.

A community hospital is a destination for cancer care

At Lancaster General Health, receiving advanced treatments closer to home has changed the battle with cancer for patients across central Pennsylvania.

Schedule an appointment

We can help you schedule an appointment or you can search our directory of specialists.